Evaluation of the efficacy and safety of fexofenadine in the management of chronic idiopathic urticaria: a prospective study with 512 patients.
Indian J Dermatol Venereol Leprol
;
2002 Mar-Apr; 68(2): 73-6
Article
in English
| IMSEAR
| ID: sea-52556
ABSTRACT
Five hundred and twelve patients with chronic idiopathic urticaria (CIU) were treated with fexofenadine at a dose on 180 mg/day. Maximum number of patients were between 20 to 40 years of age and female to male ratio was 1.451. The severity of itching was calculated on a scale of 0 to 4 and was recorded by the patients. The mean daily total symptom score (TSS) was measured as sum of the patients' pruritus and number of wheal scores (0 to 7). A mean TSS was determined for each week. Baseline TSS came down to '0' by 4 weeks in all groups except those with TSS 4. There was no correlation between the baseline TSS and degree of improvement. Of 512, 14 (2.73%) patients did not complete the study. The commonest adverse effect was headache (9.04%). There was no report of drowsiness or cardiac arrhythmia. In no patient fexofenadine had to be withdrawn because of its adverse effects.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Type of study:
Observational study
Language:
English
Journal:
Indian J Dermatol Venereol Leprol
Year:
2002
Type:
Article
Similar
MEDLINE
...
LILACS
LIS